INDICATIONS AND USAGE :

 Hepatocellular Carcinoma Sorafenib is indicated for the treatment of patients with unresectable hepatocellular carcinoma (HCC). Renal Cell Carcinoma Sorafenib is indicated for the treatment of patients with advanced renal cell carcinoma (RCC). DOSAGE & ADMINISTRATION The recommended daily dose of Sorafenib is 400 mg (2 x 200 mg tablets) taken twice daily without food (at least 1 hour before or 2 hours after a meal). Treatment should continue until the patient is no longer clinically benefiting from therapy or until unacceptable toxicity Occurs. Management of suspected adverse drug reactions may require temporary interruption and/or dose reduction of Sorafenib therapy. When dose reduction is necessary, the Sorafenib dese may be reduced to 400 mg once daily. It additional dose reduction is required. Sorafenib may be reduced to a single 400 mg dose every other day.

FIND A PRODUCT